MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations
- PMID: 19636048
- PMCID: PMC2715210
- DOI: 10.1212/WNL.0b013e3181af79e5
MRI and CSF biomarkers in normal, MCI, and AD subjects: diagnostic discrimination and cognitive correlations
Abstract
Objective: To assess the correlations of both MRI and CSF biomarkers with clinical diagnosis and with cognitive performance in cognitively normal (CN) subjects and patients with amnestic mild cognitive impairment (aMCI) and Alzheimer disease (AD).
Methods: This is a cross-sectional study with data from the Alzheimer's Disease Neuroimaging Initiative, which consists of CN subjects, subjects with aMCI, and subjects with AD with both CSF and MRI. Baseline CSF (t-tau, Abeta(1-42), and p-tau(181P)) and MRI scans were obtained in 399 subjects (109 CN, 192 aMCI, 98 AD). Structural Abnormality Index (STAND) scores, which reflect the degree of AD-like anatomic features on MRI, were computed for each subject.
Results: We found no significant correlation between CSF biomarkers and cognitive scores in any of the 3 clinical groups individually. Conversely, STAND scores correlated with both Clinical Dementia Rating-sum of boxes and Mini-Mental State Examination in aMCI and AD (p < or = 0.01). While STAND and all CSF biomarkers were predictors of clinical group membership (CN, aMCI, or AD) univariately (p < 0.001), STAND was more predictive than CSF both univariately and in combined models.
Conclusions: CSF and MRI biomarkers independently contribute to intergroup diagnostic discrimination and the combination of CSF and MRI provides better prediction than either source of data alone. However, MRI provides greater power to effect cross-sectional groupwise discrimination and better correlation with general cognition and functional status cross-sectionally. We therefore conclude that although MRI and CSF provide complementary information, MRI reflects clinically defined disease stage better than the CSF biomarkers tested.
Figures
Similar articles
-
MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.Neurology. 2009 Jul 28;73(4):294-301. doi: 10.1212/WNL.0b013e3181af79fb. Neurology. 2009. PMID: 19636049 Free PMC article.
-
Serial MRI and CSF biomarkers in normal aging, MCI, and AD.Neurology. 2010 Jul 13;75(2):143-51. doi: 10.1212/WNL.0b013e3181e7ca82. Neurology. 2010. PMID: 20625167 Free PMC article.
-
Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.Ann Neurol. 2010 Mar;67(3):308-16. doi: 10.1002/ana.21953. Ann Neurol. 2010. PMID: 20373342 Free PMC article.
-
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001. Alzheimers Dement. 2015. PMID: 26073027 Free PMC article. Review.
-
Magnetic resonance imaging characterization of brain structure and function in mild cognitive impairment: a review.J Am Geriatr Soc. 2008 May;56(5):920-34. doi: 10.1111/j.1532-5415.2008.01684.x. Epub 2008 Apr 9. J Am Geriatr Soc. 2008. PMID: 18410325 Free PMC article. Review.
Cited by
-
Neuroimaging predictors of brain amyloidosis in mild cognitive impairment.Ann Neurol. 2013 Aug;74(2):188-98. doi: 10.1002/ana.23921. Epub 2013 Sep 10. Ann Neurol. 2013. PMID: 23686534 Free PMC article.
-
Selective worsening of brain injury biomarker abnormalities in cognitively normal elderly persons with β-amyloidosis.JAMA Neurol. 2013 Aug;70(8):1030-8. doi: 10.1001/jamaneurol.2013.182. JAMA Neurol. 2013. PMID: 23797806 Free PMC article.
-
Advances in longitudinal studies of amnestic mild cognitive impairment and Alzheimer's disease based on multi-modal MRI techniques.Neurosci Bull. 2014 Apr;30(2):198-206. doi: 10.1007/s12264-013-1407-y. Epub 2014 Feb 27. Neurosci Bull. 2014. PMID: 24574084 Free PMC article. Review.
-
Role of β-Amyloidosis and Neurodegeneration in Subsequent Imaging Changes in Mild Cognitive Impairment.JAMA Neurol. 2015 Dec;72(12):1475-83. doi: 10.1001/jamaneurol.2015.2323. JAMA Neurol. 2015. PMID: 26437123 Free PMC article.
-
Total and phosphorylated tau protein as biological markers of Alzheimer's disease.Exp Gerontol. 2010 Jan;45(1):30-40. doi: 10.1016/j.exger.2009.10.010. Epub 2009 Oct 22. Exp Gerontol. 2010. PMID: 19853650 Free PMC article. Review.
References
-
- Blennow K, Hampel H. CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–613. - PubMed
-
- Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience 2000;95:721–725. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical